Business
Capricor Therapeutics Announces Late-Breaking Presentation at 2026 MDA Clinical and Scientific Conference
Late-breaking presentation at MDA to feature Phase 3 HOPE-3 results supporting Deramiocel in Duchenne muscular dystrophyHOPE-3 clinical study report (CSR)
About this update from Capricor Therapeutics, Inc.
[{"type":"text","content":"Late-breaking presentation at MDA to feature Phase 3 HOPE-3 results supporting Deramiocel in Duchenne muscular dystrophyHOPE-3 clinical study report (CSR) submitted to the U.S. Food and Drug Administration (FDA) in support of the ongoing BLA review SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that results from its Phase 3 HOPE-3 clinical study of Deramiocel in Duchenne muscular dystrophy (DMD) have been selected for a late-breaking oral presentation at the 2026 Muscular Dystrophy Association (MDA) Clinical and Scientific Conference, taking place March 8–11, 2026, in Orlando, Florida. “The selection of HOPE-3 as a late-breaking presentation at the MDA Conference recognizes the strength and growing body of clinical evidence supporting Deramiocel and its potential impact for patients living with Duchenne,” said Linda Marbán, Ph.D., Chief Executive Officer of Capricor. “We look forward to sharing these Phase 3 results with the DMD community while continuing to advance our regulatory efforts, including the recent submission of the HOPE-3 clinical study report to the FDA as part of our ongoing BLA review process. We remain focused on working toward a potential approval decision and on bringing this therapy to patients as efficiently as possible.” MDA Presentation Details Date and Time:March 11, 2026, 2:45 p.m. ETPresentation Title:Confirmation of Musculoskeletal and Cardiac Benefit in DMD from Deramiocel, an Allogeneic Cell Therapy, in the Phase 3 HOPE-3 StudyPresenter:Craig McDonald, M.D. (Professor of Physical Medicine & Rehabilitation and Pediatrics at UC Davis Health and National Principal Investigator of the HOPE-3 trial)Location:Florida 4 The CSR submission was requested by the FDA following prior regulatory interactions and is intended to address items outlined in the Complete Response Letter (CRL) and support the ongoing review of the Company’s Biologics License Application (BLA) for Deramiocel in Duchenne muscular dystrophy, including the potential assignment by the FDA of a new Prescription Drug User Fee Act (PDUFA) target action date. For more details on the MDA conference, click here. To view the conference agenda, click here. About Duchenne Muscular...